In-depth valuation analysis including DCF scenarios and peer comparisons.
AI Insight: Humana’s current price is slightly below the PERT-weighted fair value, indicating modest upside potential amid high valuation confidence. Financial health scores reveal fair but suboptimal liquidity, profitability, and growth, contributing to notable downside risk (38.9%) and high volatility (49.31%). Monte Carlo projections span a wide value range, reflecting significant uncertainty in future performance.